JP6386996B2 - 抗ｐｃｓｋ９抗体およびその使用 - Google Patents

抗ｐｃｓｋ９抗体およびその使用 Download PDF

Info

Publication number
JP6386996B2
JP6386996B2 JP2015511658A JP2015511658A JP6386996B2 JP 6386996 B2 JP6386996 B2 JP 6386996B2 JP 2015511658 A JP2015511658 A JP 2015511658A JP 2015511658 A JP2015511658 A JP 2015511658A JP 6386996 B2 JP6386996 B2 JP 6386996B2
Authority
JP
Japan
Prior art keywords
seq
antibody
agent
pcsk9
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015511658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519050A (ja
JP2015519050A5 (enExample
Inventor
フェルダウス，アンドリュー・ローレンス
ガルシア−マルティネス，レオン・エフ
デュツァー，ベンジャミン・エイチ
オジャラ，イーサン・ウェイン
コヴァセヴィッチ，ブライアン・ロバート
オルソン，ケイティ
ファン，ペイ
ビルグレン，ジェンズ・ジェイ
スチュアート，エリカ・アン
アカツカ，コリーヌ・シー
マクニール，パトリシア・ダイアン
ミッチェル，ダニエル・マリー
アリソン，ダン・スコット
ラザム，ジョン・エイ
Original Assignee
アルダーバイオ・ホールディングズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルダーバイオ・ホールディングズ・エルエルシー filed Critical アルダーバイオ・ホールディングズ・エルエルシー
Publication of JP2015519050A publication Critical patent/JP2015519050A/ja
Publication of JP2015519050A5 publication Critical patent/JP2015519050A5/ja
Application granted granted Critical
Publication of JP6386996B2 publication Critical patent/JP6386996B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
JP2015511658A 2012-05-08 2013-05-08 抗ｐｃｓｋ９抗体およびその使用 Expired - Fee Related JP6386996B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261644065P 2012-05-08 2012-05-08
US61/644,065 2012-05-08
US201261654481P 2012-06-01 2012-06-01
US61/654,481 2012-06-01
US13/795,674 US9255154B2 (en) 2012-05-08 2013-03-12 Anti-PCSK9 antibodies and use thereof
US13/795,674 2013-03-12
PCT/US2013/040112 WO2013169886A1 (en) 2012-05-08 2013-05-08 Anti-pcsk9 antibodies and use thereof

Publications (3)

Publication Number Publication Date
JP2015519050A JP2015519050A (ja) 2015-07-09
JP2015519050A5 JP2015519050A5 (enExample) 2016-06-23
JP6386996B2 true JP6386996B2 (ja) 2018-09-05

Family

ID=49548786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511658A Expired - Fee Related JP6386996B2 (ja) 2012-05-08 2013-05-08 抗ｐｃｓｋ９抗体およびその使用

Country Status (14)

Country Link
US (3) US9255154B2 (enExample)
EP (2) EP2844673A4 (enExample)
JP (1) JP6386996B2 (enExample)
KR (1) KR102137291B1 (enExample)
CN (2) CN109796533A (enExample)
AR (1) AR092005A1 (enExample)
AU (1) AU2013259562B2 (enExample)
CA (1) CA2872777A1 (enExample)
IL (1) IL235436A0 (enExample)
MX (1) MX2014013612A (enExample)
NZ (2) NZ732652A (enExample)
SG (1) SG11201407099WA (enExample)
TW (1) TW201348260A (enExample)
WO (1) WO2013169886A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
WO2015092393A2 (en) * 2013-12-17 2015-06-25 Kymab Limited Human targets
EP3104879A2 (en) * 2014-02-14 2016-12-21 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
JP2017512457A (ja) * 2014-02-21 2017-05-25 メディミューン，エルエルシー 抗ｐｃｓｋ９〜ｇｌｐ−１融合物および使用方法
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN104447619A (zh) * 2014-10-24 2015-03-25 江南大学 一种氢氯噻嗪半抗原和完全抗原及其制备方法
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US10047157B2 (en) 2014-12-19 2018-08-14 Alder Biopharmaceuticals, Inc. Humanized anti-ACTH antibodies and use thereof
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107531798B (zh) 2015-03-20 2022-02-18 奥胡斯大学 Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
MX2017013113A (es) 2015-04-16 2018-07-06 Alder Biopharmaceuticals Inc Anticuerpos anti-pacap y sus usos.
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN107406511B (zh) * 2015-12-31 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3401336A4 (en) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. ANTI-PCSK9 ANTIBODIES, ASSOCIATED ANTIGEN BINDING FRAGMENT, AND ASSOCIATED MEDICAL APPLICATION
CN107266575B (zh) 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
CA3020839A1 (en) * 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
EA201990136A1 (ru) * 2016-06-27 2019-05-31 Президент Энд Феллоуз Оф Гарвард Колледж Соединения, применимые для лечения нарушений обмена веществ
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
WO2018054240A1 (en) * 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
ES2871783T3 (es) 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
MX2019009418A (es) * 2017-02-08 2019-10-02 Esperion Therapeutics Inc Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
US20210139589A1 (en) * 2017-06-22 2021-05-13 Apexigen, Inc Anti-vista antibodies and methods of use
WO2019045856A1 (en) * 2017-08-28 2019-03-07 Systimmune, Inc. ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM
CN109897110B (zh) * 2017-12-08 2022-05-17 深圳华大生命科学研究院 纳米抗体及其制备方法
IL278710B2 (en) 2018-05-16 2025-09-01 Lib Therapeutics Llc Compositions comprising pcsk9 binding compounds and methods of use
US12103969B2 (en) * 2018-09-25 2024-10-01 Academia Sinica Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
JP7619939B2 (ja) 2018-10-05 2025-01-22 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
WO2020236670A1 (en) 2019-05-17 2020-11-26 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
EP4054625A4 (en) * 2019-11-07 2026-01-07 Medimmune Llc Endothelial Lipase Antibodies for the Treatment of Cardiovascular Diseases
PH12022551172A1 (en) * 2019-11-18 2024-02-19 Ad Pharmaceuticals Co Ltd Anti-pcsk9 antibody and use thereof
EP4126966A4 (en) 2020-03-31 2024-08-07 Seattle Children's Hospital d/b/a Seattle Children's Research Institute PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
KR20210158693A (ko) * 2020-06-24 2021-12-31 바이오스트림테크놀러지스(주) 항 ｐｃｓｋ９ 항체 및 이의 용도
JP2025522576A (ja) * 2022-06-30 2025-07-15 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体製剤及びその応用
CN115960238A (zh) * 2022-12-26 2023-04-14 河南城建学院 一种能特异性结合pcsk9抗原的纳米抗体及其制备方法
CN119569860B (zh) * 2023-09-07 2025-11-18 菲鹏生物股份有限公司 一种抗p24抗体及其应用
WO2025128837A1 (en) * 2023-12-13 2025-06-19 Systimmune, Inc. Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
US20070173473A1 (en) 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007030937A2 (en) 2005-09-16 2007-03-22 Institut De Recherches Cliniques De Montreal/I.R.C.M. Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
DK2021472T3 (da) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
US8187833B2 (en) 2006-05-08 2012-05-29 Adaerata Limited Partnership Chimeric PCSK9 proteins, cells comprising same, and assays using same
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
EP2076597A2 (en) 2006-10-09 2009-07-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008106982A2 (en) 2007-03-07 2008-09-12 Aarhus Universitet Pig model for atherosclerosis
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
EP2142217B1 (en) 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
BRPI0810551A2 (pt) 2007-04-13 2019-09-03 Novartis Ag moléculas e métodos para modulação da pró-proteína convertase subtilisina/quexina tipo 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2009027527A2 (en) 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
CA2603615A1 (en) 2007-09-21 2009-03-21 Patrick Labonte Methods of reducing viral infection and kits therefore
KR20100091191A (ko) 2007-10-26 2010-08-18 쉐링 코포레이션 항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법
CN102006890A (zh) 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 靶向脂质
CA2708171C (en) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Folate conjugates
US8227184B2 (en) 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
BRPI0907008A2 (pt) 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
EP2247729B1 (en) 2008-02-11 2019-05-01 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US20100081632A1 (en) 2008-03-06 2010-04-01 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
WO2009114475A2 (en) 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
US20110224280A1 (en) 2008-04-16 2011-09-15 Niels Fisker Nielsen Pharmaceutical Composition Comprising Anti PCSK9 Oligomers
AU2009238550B2 (en) * 2008-04-23 2014-11-27 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
US20090275053A1 (en) 2008-04-30 2009-11-05 Board Of Regents, The University Of Texas System Cell-based pcsk9 screening assay
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
EP2285399A2 (en) 2008-05-22 2011-02-23 Schering Corporation Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders
KR100985090B1 (ko) 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
WO2009147009A2 (en) 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20110172292A1 (en) 2008-06-30 2011-07-14 Hansen Jens Bo Rode Antidote oligomers
US8206943B1 (en) 2008-06-30 2012-06-26 Schering Corporation Assay for PCSK9 inhibitors
US8742082B2 (en) 2008-08-14 2014-06-03 Nestec S.A. Compositions and methods for influencing satiety, lipid metabolism, and fat utilization
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
EP4241767B1 (en) 2008-11-10 2024-10-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010056910A2 (en) 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
WO2010102195A2 (en) 2009-03-06 2010-09-10 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
AU2010260148A1 (en) 2009-06-15 2012-02-02 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
WO2011005861A1 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
SI2470656T1 (sl) 2009-08-27 2015-07-31 Idera Pharmaceuticals, Inc. Sestavek za inhibicijo ekspresije genov in njegova uporaba
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
WO2011038288A1 (en) 2009-09-25 2011-03-31 Isis Pharmaceuticals, Inc. Modulation of ttc39 expression to increase hdl
US20120252796A1 (en) 2009-10-01 2012-10-04 Harikishore Pingali Compounds for the treatment of dyslipidemia and related diseases
WO2011044643A1 (en) 2009-10-16 2011-04-21 Genetics Investments Pty. Ltd. Macronutrient sensitivity
JP2013509591A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｐｃｓｋ９イムノアッセイ
EP2494354A1 (en) 2009-10-30 2012-09-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
IN2012DN03824A (enExample) 2009-10-30 2015-08-28 Merck Sharp & Dohme
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
US20110136241A1 (en) 2009-12-08 2011-06-09 Stephen Naylor Type ii diabetes molecular bioprofile and method and system of using the same
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JP2013515005A (ja) 2009-12-17 2013-05-02 ネイティビス， インコーポレイテッド 水性組成物および方法
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
US20150080463A1 (en) 2010-03-16 2015-03-19 Bg Medicine, Inc. Methods for predicting cardiovascular events and monitoring treatment using pcsk9
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
ES2689875T3 (es) 2010-04-13 2018-11-16 Bristol-Myers Squibb Company Proteínas con un dominio de armazón a base de fibronectina que se unen a PCSK9
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA2801417C (en) 2010-06-04 2017-07-11 Kowa Company, Ltd. Optically active dibenzylamine derivative, and method for preparing thereof
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US9127280B2 (en) 2010-08-31 2015-09-08 Osaka University Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
CA2812657A1 (en) 2010-10-12 2012-04-19 Mcmaster University A method of regulating plasma lipoproteins
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2816321A1 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
EP2638063A4 (en) 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc GB1 PEPTIDE LIBRARIES AND CONNECTIONS AND SCREENING METHOD THEREFOR
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
BR112013015687A2 (pt) 2010-12-22 2016-10-11 Genentech Inc anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
KR20140006022A (ko) 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP2681556A2 (en) 2011-03-04 2014-01-08 Merck Sharp & Dohme Corp. Cd16a reporter assay for evaluation of adcc potential of biologics
US20140011236A1 (en) 2011-03-22 2014-01-09 Merch Sharp & Dohme Corp. Promoters for high level recombinant expression in fungal host cells
EP2694655A4 (en) 2011-04-08 2015-01-14 Merck Sharp & Dohme pAVEC
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
EP2723865B1 (en) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT
BR112014000392A2 (pt) 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2565757T3 (es) 2011-09-13 2016-04-06 Affiris Ag Vacuna de PCSK9
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
LT3045187T (lt) 2011-10-14 2019-07-10 Amgen Inc. Injekcijų įrenginys ir surinkimo būdas
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US9463247B2 (en) 2011-12-07 2016-10-11 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
JP6170940B2 (ja) 2011-12-20 2017-07-26 アダエラータ、リミテッド パートナーシップＡｄａｅｒａｔａ， Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体
CN110025608A (zh) 2012-01-06 2019-07-19 燿石治疗公司 降低心血管疾病风险的方法
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
KR102057540B1 (ko) 2012-02-17 2019-12-19 더 칠드런스 호스피탈 오브 필라델피아 세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
AR090259A1 (es) 2012-03-06 2014-10-29 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
MX352457B (es) 2012-05-17 2017-11-24 Cyon Therapeutics Inc Metodos y usos para inhibidores de proproteina convertasa subtilisina kexina 9 (pcsk9).
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
EP2667197B1 (en) 2012-05-25 2015-09-16 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
RU2015101113A (ru) 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
US20140194512A1 (en) 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
WO2014004987A2 (en) 2012-06-30 2014-01-03 Hellstrom Harold R Short-term infarction-based test for investigative drugs
CA2877766A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
US9956291B2 (en) 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
JP2015524439A (ja) 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
US9526720B2 (en) 2012-08-17 2016-12-27 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
US20140324460A1 (en) 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20140120091A1 (en) 2012-10-31 2014-05-01 University Of Washington Through Its Center For Commercialization Fusion proteins for therapy of autoimmune and cardiovascular disease
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
SG11201505856TA (en) 2013-03-14 2015-08-28 Daiichi Sankyo Co Ltd Novel binding proteins for pcsk9
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20140287952A1 (en) 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
ES2834113T3 (es) 2013-03-15 2021-06-16 H Lundbeck As Purificación de anticuerpos y monitorización de la pureza
US10202630B2 (en) 2013-03-15 2019-02-12 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
PT3024498T (pt) 2013-07-22 2020-03-06 Childrens Hospital Philadelphia Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
US20150037816A1 (en) 2013-08-01 2015-02-05 Atherotech, Inc. PCSK9 Function Assay
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP3104879A2 (en) 2014-02-14 2016-12-21 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy

Also Published As

Publication number Publication date
JP2015519050A (ja) 2015-07-09
AU2013259562B2 (en) 2018-05-10
US20160194408A1 (en) 2016-07-07
MX2014013612A (es) 2015-10-26
KR102137291B1 (ko) 2020-07-23
NZ732652A (en) 2018-10-26
EP2844673A1 (en) 2015-03-11
CN109796533A (zh) 2019-05-24
AU2013259562A1 (en) 2014-11-27
WO2013169886A9 (en) 2014-01-23
AR092005A1 (es) 2015-03-18
KR20150006471A (ko) 2015-01-16
CN104583237A (zh) 2015-04-29
CA2872777A1 (en) 2013-11-14
CN104583237B (zh) 2018-12-25
US20190389968A1 (en) 2019-12-26
EP3753950A2 (en) 2020-12-23
EP2844673A4 (en) 2016-04-20
NZ702304A (en) 2017-09-29
US9255154B2 (en) 2016-02-09
WO2013169886A1 (en) 2013-11-14
US10259885B2 (en) 2019-04-16
TW201348260A (zh) 2013-12-01
SG11201407099WA (en) 2014-11-27
US20130302399A1 (en) 2013-11-14
IL235436A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP2015519050A (ja) 抗ｐｃｓｋ９抗体およびその使用
JP6754456B2 (ja) 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
JP6527563B2 (ja) 抗ｃｇｒｐ組成物およびその使用
US11027018B2 (en) Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
EP2646468B1 (en) Anti-ngf compositions and use thereof
US10227402B2 (en) Anti-NGF antibodies and anti-NGF antibody fragments
US10221236B2 (en) Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
JP6300373B2 (ja) 抗バソヒビン２抗体
HK40009057A (en) Anti-pcsk9 antibodies and use thereof
EA047357B1 (ru) Применение антител или фрагментов антител против cgrp или против cgrp-r для лечения или профилактики хронических и острых форм диареи

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180810

R150 Certificate of patent or registration of utility model

Ref document number: 6386996

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees